Guardant Health, Inc. (GH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150M 300M 450M Q3 '21: 94.8M Q4 '21: 108.1M Q1 '22: 96.1M Q2 '22: 109.1M Q3 '22: 117.4M Q4 '22: 126.9M Q1 '23: 128.7M Q2 '23: 137.2M Q3 '23: 143M Q4 '23: 155.1M Q1 '24: 168.5M Q2 '24: 177.2M Q3 '24: 191.5M Q4 '24: 201.8M Q1 '25: 203.5M Q2 '25: 232.1M Q3 '25: 265.2M Q4 '25: 281.3M Q1 '26: 301.7M Q2 '26: 335M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: -107.3M Q4 '21: -98.2M Q1 '22: -123.3M Q2 '22: -130.3M Q3 '22: -144.6M Q4 '22: -146.1M Q1 '23: -134.1M Q2 '23: -119.6M Q3 '23: -113.5M Q4 '23: -197.5M Q1 '24: -99.7M Q2 '24: -100.6M Q3 '24: -117.3M Q4 '24: -126M Q1 '25: -111M Q2 '25: -106.4M Q3 '25: -99M Q4 '25: -120.8M Q1 '26: -121.3M Q2 '26: -129.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '21: -107.5M Q4 '21: -72.3M Q1 '22: -123.2M Q2 '22: -229.4M Q3 '22: -162M Q4 '22: -139.9M Q1 '23: -133.5M Q2 '23: -72.8M Q3 '23: -86.1M Q4 '23: -187M Q1 '24: -115M Q2 '24: -102.6M Q3 '24: -107.8M Q4 '24: -111M Q1 '25: -95.2M Q2 '25: -99.9M Q3 '25: -92.7M Q4 '25: -128.5M Q1 '26: -112.1M Q2 '26: -120.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 40M 80M 120M Q1 '24: 65.3M Q2 '24: 72.4M Q3 '24: 74.5M Q4 '24: 77.6M Q1 '25: 74.7M Q2 '25: 81.2M Q3 '25: 93.6M Q4 '25: 99.5M Q1 '26: 104.9M Q2 '26: 115.9M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '21: -53.1M Q4 '21: -77M Q1 '22: -28.6M Q2 '22: -111.9M Q3 '22: -78.2M Q4 '22: -90.7M Q1 '23: -74.4M Q2 '23: -94M Q3 '23: -77.8M Q4 '23: -78.7M Q1 '24: -30.3M Q2 '24: -94M Q3 '24: -51.1M Q4 '24: -64.5M Q1 '25: -62.7M Q2 '25: -60.3M Q3 '25: -35.4M Q4 '25: -26.4M Q1 '26: -65.6M Q2 '26: -57.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -75.3M Q4 '21: -101.6M Q1 '22: -51.3M Q2 '22: -135M Q3 '22: -99.9M Q4 '22: -100.8M Q1 '23: -82M Q2 '23: -100.5M Q3 '23: -80.2M Q4 '23: -82.8M Q1 '24: -37.2M Q2 '24: -99.1M Q3 '24: -55.3M Q4 '24: -83.4M Q1 '25: -67.1M Q2 '25: -65.9M Q3 '25: -45.8M Q4 '25: -54.2M Q1 '26: -71.2M Q2 '26: -69.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 96M Q3 '20: 99.6M Q1 '21: 101M Q2 '21: 101.2M Q3 '21: 101.4M Q1 '22: 101.9M Q2 '22: 102M Q3 '22: 102.3M Q1 '23: 102.7M Q2 '23: 108.8M Q3 '23: 117.7M Q1 '24: 121.7M Q2 '24: 122.4M Q3 '24: 123.1M Q1 '25: 123.9M Q2 '25: 124.1M Q3 '25: 124.8M Q1 '26: 131.3M Q2 '26: 132.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '21: -4.05 Q4 '21: -4.00 Q1 '22: -4.12 Q2 '22: -5.41 Q3 '22: -5.93 Q4 '22: -6.41 Q1 '23: -6.50 Q2 '23: -4.92 Q3 '23: -4.07 Q4 '23: -4.32 Q1 '24: -3.96 Q2 '24: -4.13 Q3 '24: -4.28 Q4 '24: -3.56 Q1 '25: -3.39 Q2 '25: -3.35 Q3 '25: -3.21 Q4 '25: -3.31 Q1 '26: -3.39 Q2 '26: -3.49 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.